On October 12, 2026 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, reported that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Mazur will provide an overview of the Company’s business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by the Company’s majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).
Maxim Growth Summit:
Conference: 2026 Maxim Growth Summit
Dates: October 12–14, 2026
Location: Hard Rock Hotel New York, New York, NY
Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company’s investor relations team.
ThinkEquity Conference:
Conference: ThinkEquity Conference
Date: October 15, 2026
Location: Mandarin Oriental, New York, NY
Presentation Date & Time: Thursday, October 15, 2026, 3:00-3:30pm ET
Please note that the presentation date and time is subject to change. Participants should refer to the final program agenda for up-to-date information.
Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company’s investor relations team.
(Press release, Citius Pharmaceuticals, OCT 12, 2026, View Source [SID1234673331])